Physician profile
Lawrence A May
NPI 1487743787
$4,162.32
in general payments reported to CMS, 2019-2025
22 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $828 · 2021: $900 · 2022: $500 · 2023: $317 · 2024: $303 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,152.30 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $602.73 | 2019-2025 | Prolia, Evenity, Repatha |
| Kowa Pharmaceuticals America, INC. | $495.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $281.30 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $248.16 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.37 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $198.37 | 2020-2022 | |
| Lilly USA, LLC | $165.50 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $139.36 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $123.20 | 2022-2025 | Dupixent |
| Exact Sciences Corporation | $113.77 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $91.38 | 2019-2021 | |
| Pfizer INC. | $72.46 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $57.27 | 2019-2021 | |
| Novo Nordisk INC | $38.52 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $32.88 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbvie INC. | $25.55 | 2023 | |
| Idorsia Pharmaceuticals US INC | $24.97 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.79 | 2021 | |
| Optinose US, INC. | $21.58 | 2019 | |
| Dexcom, INC. | $20.43 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $14.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.